688767.SH
Hangzhou Biotest Biotech Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 38.20
+4.09%Year over year
Reported trailing growth
- Revenue
- -12.1%
- EBITDA
- —
- EBIT
- -83.1%
- EPS
- -78.9%
- Free cash flow
- —
- Operating cash flow
- -39.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -38.2%
- EBITDA
- -56.9%
- EBIT
- -61.9%
- Net income
- -60.1%
- EPS
- -63.9%
- Free cash flow
- +79.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026